Danaher (NYSE:DHR – Get Free Report) was upgraded by stock analysts at UBS Group to a “strong-buy” rating in a report issued on Wednesday, Zacks reports.
A number of other equities analysts have also recently commented on the stock. Citigroup began coverage on shares of Danaher in a research note on Tuesday, May 26th. They issued a “buy” rating and a $230.00 price objective for the company. Wolfe Research cut shares of Danaher from an “outperform” rating to a “peer perform” rating in a research report on Monday, June 1st. DZ Bank initiated coverage on shares of Danaher in a report on Wednesday, June 3rd. They issued a “buy” rating and a $210.00 price target for the company. Stifel Nicolaus dropped their price target on Danaher from $260.00 to $220.00 and set a “buy” rating for the company in a research report on Wednesday, July 22nd. Finally, Weiss Ratings raised Danaher from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Wednesday, July 15th. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and five have assigned a Hold rating to the stock. According to MarketBeat, Danaher presently has an average rating of “Moderate Buy” and an average price target of $228.91.
Get Our Latest Report on Danaher
Danaher Stock Performance
Danaher (NYSE:DHR – Get Free Report) last posted its earnings results on Monday, July 20th. The conglomerate reported $1.94 EPS for the quarter, beating analysts’ consensus estimates of $1.85 by $0.09. Danaher had a return on equity of 11.04% and a net margin of 15.95%.The firm had revenue of $6.26 billion during the quarter, compared to the consensus estimate of $6.12 billion. During the same period in the prior year, the company earned $0.77 EPS. The company’s quarterly revenue was up 5.5% compared to the same quarter last year. As a group, equities analysts anticipate that Danaher will post 8.53 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Danaher
Several institutional investors have recently made changes to their positions in the company. Main Street Group LTD bought a new position in Danaher during the 1st quarter valued at about $25,000. N.E.W. Advisory Services LLC bought a new stake in Danaher in the second quarter worth about $25,000. JPL Wealth Management LLC purchased a new position in shares of Danaher during the third quarter valued at approximately $25,000. WFA of San Diego LLC purchased a new position in shares of Danaher during the second quarter valued at approximately $26,000. Finally, Hilton Head Capital Partners LLC bought a new position in shares of Danaher during the fourth quarter valued at approximately $27,000. Institutional investors own 79.05% of the company’s stock.
About Danaher
Danaher Corporation (NYSE:DHR) is a global science and technology company that develops products, services and solutions for the life sciences, biotechnology and diagnostics markets. Its businesses support pharmaceutical and biotechnology research, biomanufacturing, clinical laboratories and healthcare providers.
The company’s portfolio includes bioprocessing technologies, laboratory instruments, consumables, reagents and software. Key businesses include Cytiva, which provides biomanufacturing solutions; Beckman Coulter, which supplies laboratory diagnostics and automation systems; Leica Biosystems, which develops pathology products; and IDT, which provides genomic and nucleic acid products.
Featured Articles
- Five stocks we like better than Danaher
- MarketBeat Week in Review – 09/07 – 09/11
- Block Makes a Federal Trust Bank Move That Could Reshape Its Fintech Model
- Kroger’s Textbook Entry for Buy-and-Hold Investors
- AST SpaceMobile Looks to Extend Its 30-Day FCC Satellite Testing Window
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.
